Lithium versus Quetiapine in Depression (LQD)

The LQD study is investigating which of two medications (lithium or quetiapine) added to an antidepressant is best in helping people with treatment resistant depression. Both lithium and quetiapine are currently recommended in treatment guidelines for treatment resistant depression. The aim of the study is to address the gap in the research literature on which of these medications is most clinically and cost effective over the course of a year. Future patients will benefit from the results of the study by knowing which (if any) treatment is more likely to improve their condition over a longer duration of time.

The study is being run by South London and Maudsley NHS Foundation Trust (SLaM) across various sites including Newcastle, Durham, Oxford, and Brighton. In the North East, we are currently recruiting patients from Northumberland, Tyne and Wear NHS Foundation Trust and Tees, Esk and Wear Valleys NHS Foundation Trust. Recruitment began in December 2016 and is currently ongoing.

Who can take part?

People can take part in the study if they:

  • Are aged 18 years or over
  • Are currently experiencing depression
  • Have tried two or more antidepressants in their current depressive episode
  • Are currently taking an antidepressant
  • Do not have a diagnosis of bipolar disorder
  • Are not currently experiencing psychosis
  • Are not pregnant, currently breastfeeding, or a woman planning on getting pregnant in the near future

View the Participant Information Sheet.

For more information about the study and how to refer a patient, please contact the research team:

Kimberley.Nortey@ntw.nhs.uk or Rosie.Carr@ntw.nhs.uk